Teva Pharmaceutical Industries Ltd. announced the Food and Drug Administration approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States. Teva is preparing to launch the product in the near future. Nexium Delayed-Release Capsules, marketed by AstraZeneca, had annual sales of approximately $6 billion in the United States as of November 2014.